Related Experiment Video
Updated: Jun 25, 2026

Image-based Flow Cytometry Technique to Evaluate Changes in Granulocyte Function In Vitro
Published on: December 26, 2014
Revisiting the use of granulocyte transfusions in pediatric oncology patients
Alan S Graham1, Thomas H Price, Thomas V Brogan
1Department of Pediatrics, Division of Pediatric Critical Care, Oregon Health and Science University, Portland, OR 97239-2901, USA. grahamal@ohsu.edu
Insights
Granulocyte transfusions (GTF) in pediatric oncology patients with neutropenia showed good short-term survival, with 71% surviving hospitalization. However, long-term outcomes remain challenging for this vulnerable population.
Area of Science:
- Pediatric Hematology-Oncology
- Transfusion Medicine
- Infectious Diseases
Background:
- Neutropenia in pediatric oncology patients significantly increases infection risk.
- Serious infections in neutropenic patients often require aggressive management.
- Granulocyte transfusions (GTF) are a supportive therapy option for severe neutropenic infections.
Purpose of the Study:
- To evaluate the clinical course and outcomes of pediatric oncology patients receiving granulocyte transfusions.
- To assess the safety and efficacy of GTF in this high-risk population.
Main Methods:
- Retrospective chart review of 13 pediatric oncology patients (9 months to 16 years) receiving GTF for neutropenic infections between March 1998 and June 2000.
- Analysis of 14 GTF courses, noting number of transfusions, pre-transfusion infections, and patient outcomes.
- Evaluation of short-term outcomes including survival to discharge and extubation status.
Main Results:
- 71% (10/14) of GTF courses were followed by survival to hospital discharge.
- All 5 intubated patients were extubated after GTF.
- Despite short-term improvements, the overall mortality rate was 62% (8/13 patients), with two early deaths from invasive Aspergillus.
Conclusions:
- Granulocyte transfusions were generally well-tolerated in this cohort of septic neutropenic pediatric oncology patients.
- GTF demonstrated promising short-term survival benefits, including improved respiratory status.
- Long-term survival remains a significant challenge, highlighting the critical nature of these infections.
Objective:
To describe the clinical course of neutropenic pediatric oncology patients undergoing granulocyte transfusions (GTF).
Design:
Retrospective chart review including all children receiving GTFs between March, 1998 and June, 2000.
Setting:
Tertiary Children's Hospital and Regional Medical Center.
Patients:
Thirteen pediatric oncology patients (age, 9 mo to 16 y) with neutropenia and proven or suspected serious infection.
Interventions:
These 13 patients received a total of 14 courses of GTFs (number of transfusions per course ranged from 1 to 43, median=4.5).
Measurements And Main Results:
Twelve of the patients had documented infections before GTF. Ten of the 14 courses (71%) were followed by survival to hospital discharge. All 5 patients who were intubated before GTF were extubated afterward. Two early deaths occurred due to invasive Aspergillus. No significant differences in monitoring laboratories were found. Ultimately, 8 of 13 (62%) patients in this group died.
Conclusions:
This case series documents the course of 13 septic neutropenic pediatric oncology patients who underwent a total of 14 GTF courses. GTFs were generally well tolerated with little decline in respiratory status or organ function. Short-term survival in this population was good whereas long-term outcome remains more difficult.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Differentiation of Common Myeloid Progenitor Cells
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
